Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.

Hernandez Vargas S, Kossatz S, Voss J, Ghosh SC, Tran Cao HS, Simien J, Reiner T, Dhingra S, Fisher WE, Azhdarinia A.

Clin Cancer Res. 2019 Jul 15;25(14):4332-4342. doi: 10.1158/1078-0432.CCR-18-3312. Epub 2019 Apr 23.

PMID:
31015345
2.

New Developments in Dual-Labeled Molecular Imaging Agents.

Hernandez Vargas S, Ghosh SC, Azhdarinia A.

J Nucl Med. 2019 Apr;60(4):459-465. doi: 10.2967/jnumed.118.213488. Epub 2019 Feb 7.

3.

Application of Immuno-PET in Antibody-Drug Conjugate Development.

Carmon KS, Azhdarinia A.

Mol Imaging. 2018 Jan-Dec;17:1536012118801223. doi: 10.1177/1536012118801223. Review.

4.

Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.

Azhdarinia A, Voss J, Ghosh SC, Simien JA, Hernandez Vargas S, Cui J, Yu WA, Liu Q, Carmon KS.

Mol Pharm. 2018 Jun 4;15(6):2448-2454. doi: 10.1021/acs.molpharmaceut.8b00275. Epub 2018 May 8.

PMID:
29718672
5.

Synthesis of a Fluorescently Labeled 68Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting.

Ghosh SC, Hernandez Vargas S, Rodriguez M, Kossatz S, Voss J, Carmon KS, Reiner T, Schonbrunn A, Azhdarinia A.

ACS Med Chem Lett. 2017 Jun 6;8(7):720-725. doi: 10.1021/acsmedchemlett.7b00125. eCollection 2017 Jul 13.

6.

A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.

Ghosh SC, Rodriguez M, Carmon KS, Voss J, Wilganowski NL, Schonbrunn A, Azhdarinia A.

J Nucl Med. 2017 Nov;58(11):1858-1864. doi: 10.2967/jnumed.116.187971. Epub 2017 Jun 1.

7.

Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.

Aldrich MB, Velasquez FC, Kwon S, Azhdarinia A, Pinkston K, Harvey BR, Chan W, Rasmussen JC, Ross RF, Fife CE, Sevick-Muraca EM.

Arthritis Res Ther. 2017 May 31;19(1):116. doi: 10.1186/s13075-017-1323-z.

8.

Antibody Guided Molecular Imaging of Infective Endocarditis.

Pinkston KL, Gao P, Singh KV, Azhdarinia A, Murray BE, Sevick-Muraca EM, Harvey BR.

Methods Mol Biol. 2017;1535:229-241.

PMID:
27914083
9.

LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.

Gong X, Azhdarinia A, Ghosh SC, Xiong W, An Z, Liu Q, Carmon KS.

Mol Cancer Ther. 2016 Jul;15(7):1580-90. doi: 10.1158/1535-7163.MCT-16-0114. Epub 2016 May 20.

10.

Fluorescently-tagged anti-ganglioside antibody selectively identifies peripheral nerve in living animals.

Massaad CA, Zhang G, Pillai L, Azhdarinia A, Liu W, Sheikh KA.

Sci Rep. 2015 Oct 30;5:15766. doi: 10.1038/srep15766.

11.

Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging.

Ghosh SC, Azhdarinia A.

Curr Med Chem. 2015;22(29):3390-404. Review.

PMID:
26337105
12.

Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.

Ghosh SC, Pinkston KL, Robinson H, Harvey BR, Wilganowski N, Gore K, Sevick-Muraca EM, Azhdarinia A.

Nucl Med Biol. 2015 Feb;42(2):177-83. doi: 10.1016/j.nucmedbio.2014.09.009. Epub 2014 Oct 5.

PMID:
25457653
13.

Deglycosylation of mAb by EndoS for improved molecular imaging.

Gao P, Pinkston KL, Wilganowski N, Robinson H, Azhdarinia A, Zhu B, Sevick-Muraca EM, Harvey BR.

Mol Imaging Biol. 2015 Apr;17(2):195-203. doi: 10.1007/s11307-014-0781-9.

PMID:
25135058
14.

Stable confinement of positron emission tomography and magnetic resonance agents within carbon nanotubes for bimodal imaging.

Cisneros BT, Law JJ, Matson ML, Azhdarinia A, Sevick-Muraca EM, Wilson LJ.

Nanomedicine (Lond). 2014 Nov;9(16):2499-509. doi: 10.2217/nnm.14.26.

15.

Targeting pili in enterococcal pathogenesis.

Pinkston KL, Singh KV, Gao P, Wilganowski N, Robinson H, Ghosh S, Azhdarinia A, Sevick-Muraca EM, Murray BE, Harvey BR.

Infect Immun. 2014 Apr;82(4):1540-7. doi: 10.1128/IAI.01403-13. Epub 2014 Jan 22.

16.

Photons across medicine: relating optical and nuclear imaging.

Nordstrom R, Cherry S, Azhdarinia A, Sevick-Muraca E, Vanbrocklin H.

Biomed Opt Express. 2013 Nov 5;4(12):2751-62. doi: 10.1364/BOE.4.002751. eCollection 2013.

17.

A peptide probe for targeted brown adipose tissue imaging.

Azhdarinia A, Daquinag AC, Tseng C, Ghosh SC, Ghosh P, Amaya-Manzanares F, Sevick-Muraca E, Kolonin MG.

Nat Commun. 2013;4:2472. doi: 10.1038/ncomms3472.

18.

In vivo imaging of orthotopic prostate cancer with far-red gene reporter fluorescence tomography and in vivo and ex vivo validation.

Lu Y, Darne CD, Tan IC, Wu G, Wilganowski N, Robinson H, Azhdarinia A, Zhu B, Rasmussen JC, Sevick-Muraca EM.

J Biomed Opt. 2013 Oct;18(10):101305. doi: 10.1117/1.JBO.18.10.101305.

19.

Tumor margin detection using quantitative NIRF molecular imaging targeting EpCAM validated by far red gene reporter iRFP.

Zhu B, Wu G, Robinson H, Wilganowski N, Hall MA, Ghosh SC, Pinkston KL, Azhdarinia A, Harvey BR, Sevick-Muraca EM.

Mol Imaging Biol. 2013 Oct;15(5):560-8. doi: 10.1007/s11307-013-0637-8.

PMID:
23619897
20.

Advancing the translation of optical imaging agents for clinical imaging.

Sevick-Muraca EM, Akers WJ, Joshi BP, Luker GD, Cutler CS, Marnett LJ, Contag CH, Wang TD, Azhdarinia A.

Biomed Opt Express. 2013 Jan 1;4(1):160-70. doi: 10.1364/BOE.4.000160. Epub 2012 Dec 18.

21.

Multimodal chelation platform for near-infrared fluorescence/nuclear imaging.

Ghosh SC, Ghosh P, Wilganowski N, Robinson H, Hall MA, Dickinson G, Pinkston KL, Harvey BR, Sevick-Muraca EM, Azhdarinia A.

J Med Chem. 2013 Jan 24;56(2):406-16. doi: 10.1021/jm300906g. Epub 2013 Jan 8.

PMID:
23214723
22.

Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.

Hall MA, Pinkston KL, Wilganowski N, Robinson H, Ghosh P, Azhdarinia A, Vazquez-Arreguin K, Kolonin AM, Harvey BR, Sevick-Muraca EM.

J Nucl Med. 2012 Sep;53(9):1427-37. doi: 10.2967/jnumed.112.106302. Epub 2012 Aug 7.

23.

Design of peptide imaging agents for whole-body and intraoperative molecular imaging.

Moss JA, Vāvere AL, Azhdarinia A.

Curr Med Chem. 2012;19(20):3255-65. Review.

PMID:
22664243
24.

Quantifying multimodal contrast agent biological activity using near-infrared flow cytometry.

Hall MA, Aldrich MB, Azhdarinia A, Lachance PA, Robinson H, Hazen A, Haviland DL, Sevick-Muraca EM.

Contrast Media Mol Imaging. 2012 May-Jun;7(3):338-45. doi: 10.1002/cmmi.502.

PMID:
22539404
25.

Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.

Azhdarinia A, Ghosh P, Ghosh S, Wilganowski N, Sevick-Muraca EM.

Mol Imaging Biol. 2012 Jun;14(3):261-76. doi: 10.1007/s11307-011-0528-9. Review.

26.

Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.

Azhdarinia A, Wilganowski N, Robinson H, Ghosh P, Kwon S, Lazard ZW, Davis AR, Olmsted-Davis E, Sevick-Muraca EM.

Bioorg Med Chem. 2011 Jun 15;19(12):3769-76. doi: 10.1016/j.bmc.2011.04.054. Epub 2011 May 6.

27.

Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model.

Rodenberg E, Azhdarinia A, Lazard ZW, Hall M, Kwon SK, Wilganowski N, Salisbury EA, Merched-Sauvage M, Olmsted-Davis EA, Sevick-Muraca EM, Davis AR.

Tissue Eng Part A. 2011 Oct;17(19-20):2487-96. doi: 10.1089/ten.TEA.2011.0007. Epub 2011 Aug 2.

PMID:
21599541
28.

Imaging prostate cancer lymph node metastases with a multimodality contrast agent.

Hall MA, Kwon S, Robinson H, Lachance PA, Azhdarinia A, Ranganathan R, Price RE, Chan W, Sevick-Muraca EM.

Prostate. 2012 Feb 1;72(2):129-46. doi: 10.1002/pros.21413. Epub 2011 May 2.

PMID:
21538422
29.

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.

Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L.

Cancer Biother Radiopharm. 2008 Jun;23(3):292-300. doi: 10.1089/cbr.2007.0448.

PMID:
18593362
30.

Technologies for translational imaging using generators in oncology.

Schechter NR, Yang DJ, Azhdarinia A, Chanda M.

Recent Pat Anticancer Drug Discov. 2007 Nov;2(3):251-8. Review.

PMID:
18221069
31.

Infrared-based module for the synthesis of 68Ga-labeled radiotracers.

Azhdarinia A, Yang DJ, Chao C, Mourtada F.

Nucl Med Biol. 2007 Jan;34(1):121-7.

PMID:
17210469
32.

Radiolabeled L-lysine for tumor imaging.

Karacalioglu AO, Yang DJ, Azhdarinia A, Mendez R, Oh C, Kohanim S, Chanda M, Greenwell AC, Yu DF, Kim EE.

Acad Radiol. 2006 Nov;13(11):1327-37.

PMID:
17070450
33.

Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL.

Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Kim EE.

Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):354-62. Epub 2006 Sep 22.

PMID:
17021817
34.

PET and planar imaging of tumor hypoxia with labeled metronidazole.

Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, Greenwell AC, Yu DF, Kim EE.

Acad Radiol. 2006 May;13(5):598-609.

PMID:
16627201
35.

(99m)Tc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals.

Yang DJ, Ozaki K, Oh CS, Azhdarinia A, Yang T, Ito M, Greenwell A, Bryant J, Kohanim S, Wong VK, Kim EE.

Pharm Res. 2005 Sep;22(9):1471-9. Epub 2005 Aug 24.

PMID:
16132359
36.

Regional radiochemotherapy using in situ hydrogel.

Azhdarinia A, Yang DJ, Yu DF, Mendez R, Oh C, Kohanim S, Bryant J, Kim EE.

Pharm Res. 2005 May;22(5):776-83. Epub 2005 May 17.

PMID:
15906173
37.

Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.

Schechter NR, Wendt RE 3rd, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK.

J Nucl Med. 2004 Oct;45(10):1683-7.

38.

Assessment of therapeutic tumor response using 99mtc-ethylenedicysteine-glucosamine.

Yang D, Yukihiro M, Yu DF, Ito M, Oh CS, Kohanim S, Azhdarinia A, Kim CG, Bryant J, Kim EE, Podoloff D.

Cancer Biother Radiopharm. 2004 Aug;19(4):443-56.

PMID:
15453959
39.

Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex.

Yang DJ, Bryant J, Chang JY, Mendez R, Oh CS, Yu DF, Ito M, Azhdarinia A, Kohanim S, Edmund Kim E, Lin E, Podoloff DA.

Anticancer Drugs. 2004 Mar;15(3):255-63.

PMID:
15014359
40.

Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents.

Yang DJ, Kim CG, Schechter NR, Azhdarinia A, Yu DF, Oh CS, Bryant JL, Won JJ, Kim EE, Podoloff DA.

Radiology. 2003 Feb;226(2):465-73.

PMID:
12563141
41.

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.

Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R 3rd, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA.

Anticancer Drugs. 2003 Jan;14(1):49-56.

PMID:
12544258
42.

Assessment of antiangiogenic effect using 99mTc-EC-endostatin.

Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA.

Cancer Biother Radiopharm. 2002 Apr;17(2):233-45.

PMID:
12030117
43.

In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V.

Yang DJ, Azhdarinia A, Wu P, Yu DF, Tansey W, Kalimi SK, Kim EE, Podoloff DA.

Cancer Biother Radiopharm. 2001 Feb;16(1):73-83.

PMID:
11279800

Supplemental Content

Loading ...
Support Center